敗血症藥物市場規模、佔有率和成長分析（按藥物類別、病原體類型、治療類型、給藥途徑、最終用戶和地區分類）－2026-2033年產業預測

預計到 2024 年，全球敗血症藥物市場規模將達到 72.6 億美元，到 2025 年將達到 74.3 億美元，到 2033 年將達到 89.1 億美元，預測期（2026-2033 年）的複合年成長率為 2.3%。

全球敗血症治療市場正經歷強勁成長，主要受加護病房(ICU) 收治人數不斷上升（尤其是在老齡化人口中）以及抗藥性感染疾病日益增多（導致傳統抗生素療效降低）的推動。醫院對免疫標靶治療療法和體外療法的巨額投資，推動了對速效非抗生素療法的需求。同時，政府支持和創業投資對醫療創新的投入也進一步增強了這一成長動能。新進入市場的企業正在開發先進的血液淨化設備和免疫標靶治療，以便在重症監護環境中進行快速介入。然而，市場仍面臨諸多挑戰，包括高昂的研發成本、漫長的法規核准流程、對敗血症的認知不足、診斷延遲、醫院採購流程複雜以及低收入地區醫療基礎設施匱乏等，這些都可能阻礙市場擴張。

全球膿毒症藥物市場促進因素

全球敗血症治療市場的發展動力源自於應對敗血症的迫切需求，敗血症是全球醫院死亡的主要原因之一。隨著醫療系統面臨加加護病房(ICU) 收治人數不斷增加、人口老化以及抗生素抗藥性感染疾病等挑戰，亟需更有效的治療方案。醫院被迫加強對這項嚴重疾病的應對，這需要開發超越傳統抗生素治療的創新治療方法和醫療設備。這種情況凸顯了推動膿毒症管理解決方案的重要性，以改善患者預後並減輕這項嚴峻醫療挑戰帶來的負擔。

限制全球膿毒症藥物市場的因素

全球敗血症治療市場面臨許多挑戰，主要原因是新治療方法核准成本高且流程漫長。臨床試驗需要嚴格的安全通訊協定，並招募大規模加護病房患者，這阻礙了小型公司進入市場，也抑制了整體成長。此外，鑑於這些治療方法會與脆弱的免疫系統相互作用，人們越來越擔心其安全性。監管要求增加了對大量數據和嚴格監督的需求，進一步複雜化了核准流程，並增加了該領域潛在開發人員面臨的障礙。

全球膿毒症治療市場趨勢

全球敗血症治療市場正經歷著向創新治療方案的重大轉變，這主要受敗血症發病率上升和醫療專業人員認知度提高的推動。這一趨勢的特點是研發活動激增，包括針對敗血症的先進生物製藥、免疫療法和抗生素的推出。此外，數位健康科技和個人化醫療的融合正在改善患者管理和治療效果。值得注意的是，該市場也高度重視製藥公司與研究機構之間的策略合作，以加速藥物研發。隨著全球醫療系統將膿毒症管理列為優先事項，對治療藥物的投資至關重要。

目錄

介紹

• 調查目標
• 市場定義和範圍

調查方法

• 調查過程
• 二手資料和一手資料方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭格局概述

市場動態與展望

• 總體經濟指標
• 促進因素和機遇
• 限制與挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場考察

• 關鍵成功因素
• 影響市場的因素
• 關鍵投資機會
• 生態系測繪
• 市場吸引力指數（2025）
• PESTEL 分析
• 價值鏈分析
• 定價分析
• 案例研究
• 監管環境
• 技術評估
• 技術評估
• 監管環境

全球膿毒症藥物市場規模（按藥物類別和複合年成長率分類）（2026-2033 年）

• 抗生素
• 抗真菌藥物
• 皮質類固醇
• 免疫調節劑
• 血管加壓藥
• 止痛藥和鎮靜劑
• 抗凝血劑

全球敗血症藥物市場規模（按病原體類型和複合年成長率分類）（2026-2033 年）

• 細菌性敗血症
• 黴菌性敗血症
• 病毒性敗血症

全球敗血症治療市場規模（依治療方法分類）及複合年成長率（2026-2033 年）

• 液體復甦
• 血液淨化技術
• 症狀支持治療
• 標靶免疫療法

全球敗血症藥物市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 靜脈注射
• 口服
• 其他

全球膿毒症治療市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 門診手術中心
• 診所
• 研究和學術機構

全球敗血症治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co., Inc.
• Johnson & Johnson
• AbbVie Inc.
• Eli Lilly and Company
• AstraZeneca plc
• Bayer AG
• Baxter International Inc.
• Becton, Dickinson and Company（BD）
• Thermo Fisher Scientific Inc.
• CSL Behring
• Grifols SA
• BioMerieux SA
• Bio-Rad Laboratories
• Shionogi & Co., Ltd.
• Sandoz（Novartis division）
• Takeda Pharmaceutical Company Limited

結論與建議

Global Sepsis Therapeutics Market size was valued at USD 7.26 Billion in 2024 and is poised to grow from USD 7.43 Billion in 2025 to USD 8.91 Billion by 2033, growing at a CAGR of 2.3% during the forecast period (2026-2033).

The global sepsis therapeutics market is experiencing robust growth driven by a rising number of ICU admissions, particularly among the aging population, and an increase in drug-resistant infections that diminish the efficacy of traditional antibiotics. The demand for rapid-acting non-antibiotic therapies is escalating, spurred by significant hospital investments in immune-targeted and extracorporeal treatments, while governmental support and venture capital investment in medtech innovations enhance this momentum. New players in the market are developing advanced blood purification devices and immune-targeted therapies to facilitate quicker intervention in critical care settings. Nonetheless, challenges remain, including high development costs, slow regulatory processes, limited awareness of sepsis, late diagnoses, complex procurement dynamics in hospitals, and inadequate healthcare infrastructure in low-income regions that may impede market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sepsis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sepsis Therapeutics Market Segments Analysis

Global Sepsis Therapeutics Market is segmented by Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Antibiotics, Antifungals, Corticosteroids, Immunomodulators, Vasopressors, Analgesics and Sedatives and Anticoagulants. Based on Pathogen Type, the market is segmented into Bacterial Sepsis, Fungal Sepsis and Viral Sepsis. Based on Treatment Type, the market is segmented into Fluid Resuscitation, Blood Purification Techniques, Symptomatic and Supportive Care and Targeted Immunotherapy. Based on Route of Administration, the market is segmented into Intravenous, Oral and Others. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Clinics and Research and Academic Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sepsis Therapeutics Market

The global sepsis therapeutics market is driven by the urgent need to address sepsis, a major contributor to hospital mortality rates internationally. As health systems grapple with increasing ICU admissions, an aging population, and the challenge of antibiotic-resistant infections, there is a pressing demand for more effective treatment options. Hospitals are seeking to enhance their response to this critical condition, necessitating the development of innovative therapies and medical devices that go beyond conventional antibiotic treatments. This dynamic landscape underscores the importance of advancing sepsis management solutions to improve patient outcomes and reduce the burden of this severe healthcare challenge.

Restraints in the Global Sepsis Therapeutics Market

The Global Sepsis Therapeutics market faces significant challenges due to the high costs and lengthy processes associated with securing approval for new treatments. Clinical trials demand recruitment of substantial cohorts of intensive care unit patients alongside stringent safety protocols, which can deter smaller companies from entering the market and impede overall growth. Additionally, there is heightened concern regarding the safety of these treatments, given their interaction with vulnerable immune systems. In response to regulatory requirements, the necessity for extensive data and oversight has increased, further complicating the approval process and adding to the obstacles faced by potential developers in this field.

Market Trends of the Global Sepsis Therapeutics Market

The Global Sepsis Therapeutics market is witnessing a significant shift toward innovative treatment solutions driven by rising incidences of sepsis and increasing awareness among healthcare professionals. This trend is marked by a surge in research and development efforts, leading to the introduction of advanced biologics, immunotherapies, and antibiotics specifically targeting sepsis. Furthermore, the integration of digital health technologies and personalized medicine is enhancing patient management and outcomes. The market is also experiencing a strategic focus on partnerships and collaborations between pharmaceutical companies and research institutions to accelerate drug development. As healthcare systems globally prioritize sepsis management, investment in therapeutics is becoming paramount.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment
• Technology Assessment
• Regulatory Landscape

Global Sepsis Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antibiotics
• Antifungals
• Corticosteroids
• Immunomodulators
• Vasopressors
• Analgesics and Sedatives
• Anticoagulants

Global Sepsis Therapeutics Market Size by Pathogen Type & CAGR (2026-2033)

• Market Overview
• Bacterial Sepsis
• Fungal Sepsis
• Viral Sepsis

Global Sepsis Therapeutics Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Fluid Resuscitation
• Blood Purification Techniques
• Symptomatic and Supportive Care
• Targeted Immunotherapy

Global Sepsis Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Oral
• Others

Global Sepsis Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Research and Academic Institutes

Global Sepsis Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • US
  • Canada
• Europe (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Novartis division)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations